Annual Report for the Year Ended 31 December 2022

Ondine Biomedical Inc.

23 May 2023

 

23 May 2023

Ondine Biomedical Inc.

("Ondine Biomedical", "Ondine" or the "Company")

Annual Report for the Year Ended 31 December 2022

Ondine Biomedical (AIM: OBI) announces that its Annual Report for the year ended 31 December 2022 was posted on 23 May 2022 and is available on the Ondine website at: https://ondinebio.com/investors/reports-documentation/

Ondine Biomedical Inc.
Angelika Vance, Corporate Communications	+001 (1) 604 838 2702
Singer Capital Markets (Nominated Adviser and Joint Broker)
Aubrey Powell, Asha Chotai, Sam Butcher	[phone]
RBC Capital Markets (Joint Broker)
Rupert Walford, Kathryn Deegan	[phone]
Vane Percy & Roberts (Media Contact)
Simon Vane Percy, Amanda Bernard	[phone]

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Ondine's nasal photodisinfection technology is approved in several jurisdictions under the brand name Steriwave™. It has been awarded the CE mark and, in the US, has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.

 

END